Article
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.
Cancer research - 1 May 2008
Shafee Norazizah, Smith Christopher R, Wei Shuanzeng, Kim Yoon, Mills Gordon B, Hortobagyi Gabriel N, Stanbridge Eric J, Lee Eva Y-H P
Abstract excerpt
The majority of BRCA1-associated breast cancers are basal cell-like, which is associated with a poor outcome. Using a spontaneous mouse mammary tumor model, we show that platinum compounds, which generate DNA breaks during the repair process, are more effective than doxorubicin in Brca1/p53-mutated tumors. At 0.5 mg/kg of daily cisplatin treatment, 80% primary tumors (n = 8) show complete pathologic response. At...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.